Hassan S,Shah H,Shawana S H .2020 .Dysregulated epidermal growth factor and tumor growth factor-beta receptor signaling through GFAP-ACTA2 protein interaction in liver fibrosis. Pak J Med Sci, 10(4) : 782-787.
Raoul J,Forner A,Bolondi L,Cheung TT,Kloeckner R .2018 .Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev, 11 : 28-36.
Grégory J,Créquit P,Vilgrain V,Ronot M,Boutron I. .2020 .Results of trials assessing transarterial chemoembolization for treating hepatocellular carcinoma are critically underreported. Eur Radiol, 10(10) : 5633-5640.
Liu Z,Lin Y,Zhang J,Zhang Y,Li Y,Liu Z .2019 .Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res, 10(1) : 447.
Sadeghi S,Bejjani A,Finn RS .2019 .Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am, 06(4) : 695-715.
Feng F,Jiang Q,Jia H,Sun H,Chai Y,Li X .2018 .Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network metaanalysis. Pharmacol Res, 06 : 89-101.
Zhou J,Sun H,Wang Z,Cong W,Wang J,Zeng M .2020 .Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 10(6) : 682-720.
Shao L,Wang X,Yu Y,Xie J .2021 .Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer. Transl Cancer Res, 10(8) : 3739-3747.
Wong JK,Lim HJ,Tam VC,Burak KW,Dawson LA,Chaudhury P .2023 .Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. Cancer Treat Rev, 10 : 102526.
Tang J,Sui C,Wang D,Lu X,Luo G,Zhao Q .2020 .Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics, 10(12) : 5384-5397.
Cao W,Liu J,Wang L,Li M,Verstegen MMA,Yin Y .2019 .Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis, 10(1) : 145-154.
Cheng A,Hsu C,Chan SL,Choo S,Kudo M. .2019 .Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol, 09(2) : 307-319.
Celsa C,Cabibbo G,Pagano D,Marco VD,Cammà C .2020 .Gruttadauria S. Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. J Laparoendosc Adv Surg Tech A, 10(10) : 1048-1053.
Yang G,Xiong Y,Sun J,Wang G,Li W,Tang T .2020 .The efficacy of microwave ablation versus liver resection in the treatment of hepatocellular carcinoma and liver metastases: A systematic review and meta-analysis. Int J Surg, 03 : 85-93.
Anwanwan D,Singh SK,Singh S,Saikam V,Singh R. .2019 .1):188314. Biochim Biophys Acta Rev Cancer, 10 : .
Kim KW .2019 .Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer. Radiology, 10(3) : 704-706.
Meyer T,Fox R,Ma YT,Ross PJ,James MW,Sturgess R .2017 .Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol, 1253(17) : 30156-5.
Kimura Y,Kaneko R,Yano Y,Kamada K,Ikehara T,Nagai H,Asian Pac J Cancer Prev H .2020 .The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE. , 21(6) : 1797-1805.
Kudo M,Ueshima K,Ikeda M,Torimura T,Tanabe N,Aikata H .2020 .Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. -318934, 10(8) : 1492-1501.
Varghese J,Kedarisetty C,Venkataraman J,Srinivasan V,Deepashree T,Uthappa M .2017 .Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience. , 10(2) : 247-254.